TUMOR IMMUNOLOGY Flashcards
Estrogen/progesterone receptors
Cell surface markers
Estrogen/progesterone receptors
Cell surface markers
Thyroglobulin (TG)
Proteins
Immunoglobulins (Ig) and Ig light chains
Proteins
Alpha-1-fetoprotein (AFP)
Oncofetal antigens
Carcinoembryonic antigen (CEA)
Oncofetal antigens
CA 125
Carbohydrate antigens
CA 15-3
Carbohydrate antigens
CA 19-9 (related to Lewis antigens)
Blood group antigens
Prostate-specific antigen (PSA)
Enzymes/isoenzym es
Alkaline phosphatase (ALKP)
Enzymes/isoenzym es
Neuron specific enolase
Enzymes/isoenzym es
Human chorionic gonadotropin (hCG)
Hormones
Calcitonin
Hormones
Gastrin
Hormones
Prognosis for hormone therapy in breast cancer
Estrogen/progesterone receptors
Clonality and lineage of white blood cell neoplasms
CD markers on white blood cells
Well differentiated papillary or follicular thyroid carcinoma
Thyroglobulin (TG)
Multiple myeloma and lymphoid malignancies
Immunoglobulins (Ig) and Ig light chains
Germ cell carcinoma, hepatocellular carcinoma
Alpha-1-fetoprotein (AFP)
Colorectal carcinoma and some others
Carcinoembryonic antigen (CEA)
Ovarian cancer
CA 125
Breast Cancer
CA 15-3
Pancreatic and gastrointestin al cancers
CA 19-9 (related to Lewis antigens)
Prostate cancer
Prostate-specific antigen (PSA)
Bone and liver cancer
Alkaline phosphatase (ALKP)
Neural tissue neoplasms
Neuron specific enolase
Germ cell carcinoma, trophoblastic tumors
Human chorionic gonadotropin (hCG)
Medullary thyroid cancer
Calcitonin
Pancreatic gastrinoma
Gastrin
Prostate; Digital rectal exam; Men over 50 and with at least 10 years of life expectancy
Prostate-specific antigen (PSA, total and free)
Colorectal; Genetic testing; Subjects over 50 years old for occult blood; genetic testing in high-risk subjects
Fecal occult blood
Liver; Ultrasound; High-risk subjects
Alpha-1-fetoprotein (AFP)
Ovarian; Ultrasound; Subjects with family history of ovarian cancer
Carbohydrate antigen 125 (CA 125)
Nonseminomatous; Germ cell cancer ; Liver cancer
AFP (alpha-1- fetoprotein)
1, 2, 3, 4
Fetal liver and yolk sac, adult liver
AFP (alpha-1- fetoprotein)
Pregnancy, non neoplastic liver disease
AFP (alpha-1- fetoprotein)
Screening for high-risk populations for liver cancer as those with liver cirrhosis and chronic hepatitis
AFP (alpha-1- fetoprotein)
2
MHC class I
Β-2 microglobulin
Inflammatory high cell turnover conditions
Β-2 microglobulin
Higher levels imply poor prognosis in multiple myeloma
Β-2 microglobulin
Familial medullary thyroid carcinoma
Calcitonin and Ca++ (serum calcium)
N/A
Thyroid
Calcitonin and Ca++ (serum calcium)
In hypercalcemia, increased calcitonin is expected.
Calcitonin and Ca++ (serum calcium)
Can be elevated in other forms of cancer
Calcitonin and Ca++ (serum calcium)
Serum Ca++ may be low when calcitonin is in medullary carcinoma
Calcitonin and Ca++ (serum calcium)
White blood cell (WBC)
CD markers (cluster of differentiation in WBC)
N/A
All WBCs
CD markers (cluster of differentiation in WBC)
WBC increase such as infection
CD markers (cluster of differentiation in WBC)
An array of CD markers are associated with WBC malignancies
CD markers (cluster of differentiation in WBC)
Colorectal; Breast
CEA (Carcinoembryonic antigen)
2, 3, 4
Tissues of entodermal origin
CEA (Carcinoembryonic antigen)
Renal failure, non neoplastic liver and intestinal disease, age
CEA (Carcinoembryonic antigen)
Values increased with age and in smokers
CEA (Carcinoembryonic antigen)
Ovarian adenocarcinoma
CA125 (CA = carbohydrate antigen)
1, 2, 3, 4
Various
CA125 (CA = carbohydrate antigen)
Endometriosis, pelvic inflammatory disease, uterine fibroids, and pregnancy
CA125 (CA = carbohydrate antigen)
Don’t collect specimen during menstruation (false increase
CA125 (CA = carbohydrate antigen)
Breast ; Can be increased in pancreatic, lung, colorectal, ovarian, and liver cancers
CA15-3
4
Mammary tissue
CA15-3
Benign liver disease; Benign breast disease
CA15-3
Epitope of episialin. 15-3 is monoclonal antibody.; Others are 27.29 and 549 4
CA15-3
Pancreatic
CA 19-9
1, 2, 4
Sialyated Lewis a blood group antigen
CA 19-9
Benign hepatobiliary and pancreatic conditions
CA 19-9
Can be elevated in some nonpancreatic malignancies.
CA 19-9
Subjects who are Lewis a and b negative cannot synthesize CA 19-9
CA 19-9
Breast 2
ER/PR (Estrogen/progesterone receptors)
Breast N/A
ER/PR (Estrogen/progesterone receptors)
breast cancers and adenocarcinoma benefit from estrogen/ progesterone reduction therapy.
ER/PR (Estrogen/progesterone receptors)